龙沙集团(场外交易代码:LZAGY)股票评级获加拿大皇家银行上调——MarketBeat
Lonza Group (OTCMKTS:LZAGY) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
生命科学资讯
生物技术与制药领域的最新动态
加拿大皇家银行将龙沙集团（LZAGY）评级上调至2026年2月跑赢大盘 - Meyka
RBC upgrades Lonza Group AG (LZAGY) to Outperform Feb 2026 - Meyka
龙沙集团(OTCMKTS:LZAGY)交易量异常飙升——买入时机已到？——MarketBeat
Lonza Group (OTCMKTS:LZAGY) Sees Unusually-High Trading Volume - Time to Buy? - MarketBeat
从毒理学起步加速新药临床试验申请：与龙沙进行快速问答——BioPharm International
Speed-to-IND Starts with Toxicology: A Rapid-Fire Q&A with Lonza - BioPharm International
龙沙集团战略转型驱动强劲增长与股东回报——特别新闻
Lonza’s Strategic Pivot Fuels Robust Growth and Shareholder Returns - AD HOC NEWS
龙沙集团发布部分信息不明公告，细节模糊引关注——TipRanks
Lonza Issues Partially Unreadable Release, Leaving Details Unclear - TipRanks
龙沙集团(OTCMKTS:LZAGY)在扎克斯研究机构评级被下调至"强力卖出" - MarketBeat
Lonza Group (OTCMKTS:LZAGY) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
2026年展望：注射剂CDMO市场——DCAT价值链洞察
2026 Outlook: CDMO Market for Injectables - DCAT Value Chain Insights
龙沙集团(LONN)获瑞银给予买入评级 - 《环球邮报》
Lonza Group Ltd (LONN) Gets a Buy from UBS - The Globe and Mail
巴克莱重申对龙沙集团（LONN）的买入评级 - 《环球邮报》
Barclays Reaffirms Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
巴克莱银行重申对龙沙集团（LONN）的买入评级 - 《环球邮报》
Barclays Reaffirms Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
分析师对医疗保健公司提出见解：爱德士实验室（IDXX）与龙沙集团（其他LZAGY）——《环球邮报》报道
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Lonza Group (OtherLZAGY) - The Globe and Mail
龙沙集团(VTX:LONN)一年内45%的盈利增长未能转化为股东收益——雅虎财经
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period - Yahoo Finance
财报电话会议纪要：龙沙集团2025年第四季度业绩未达预期，股价下跌9% - Investing.com
Earnings call transcript: Lonza misses Q4 2025 forecasts, stock drops 9% - Investing.com
德意志银行维持对龙沙集团（LZAGY）2026年2月“买入”评级 - 迈卡
Deutsche Bank Maintains Buy on Lonza Group AG (LZAGY) Feb 2026 - Meyka
合同制药商龙沙预测2026年销售增长放缓 - MSN
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - MSN
龙沙集团：默默驱动下一波生物科技浪潮的隐形引擎 - 特别报道
Lonza Group AG: The Silent Engine Powering the Next Wave of Biotech - AD HOC NEWS
瑞士合同制药商龙沙预测2026年销售增长将放缓——MSN报道
Contract drug manufacturer Lonza forecasts slower sales growth for 2026 - MSN
CDMO占据新闻头条——龙沙传递出明确的实力信号 - 欧洲生物技术杂志
CDMOs dominate the headlines – and Lonza delivers a clear message of strength - European Biotechnology Magazine
龙沙集团销售额因新合同势头而增长 - MSN
Lonza sales grow on new contract momentum - MSN